C1 inhibitor function using contact-phase proteases as target: Evaluation of an innovative assay

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 9, 2015, Pages 1103-1111

  Ghannam, A ^a,b   Sellier, P ^a,b   Defendi, F ^a,c   Favier, B ^a   Charignon, D ^a,c   Lopez Lera A ^d,e   Lopez Trascasa M ^d,e   Ponard, D ^c   Drouet, C ^a,c  

^a UNIV GRENOBLE ALPES   (France)

^b KininX SAS   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

angioedema; C1 inhibitor; contact phase; diagnostic assay

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMIDASE; BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; CONTACT PHASE PROTEASE; ESTROGEN; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; PREKALLIKREIN; PROTEINASE; UNCLASSIFIED DRUG; KININOGEN; PEPTIDE HYDROLASE; PROTEIN BINDING;

ADULT; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LIMIT OF DETECTION; MALE; NORMAL HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; ANGIOEDEMAS, HEREDITARY; BIOASSAY; IMMUNOLOGY; METABOLISM; PROCEDURES; REFERENCE VALUE; STANDARDS;

ALPHA-MACROGLOBULINS; ANGIOEDEMAS, HEREDITARY; BIOLOGICAL ASSAY; COMPLEMENT C1 INACTIVATOR PROTEINS; ESTROGENS; FACTOR XIIA; FEMALE; HUMANS; KININOGENS; MALE; PEPTIDE HYDROLASES; PREKALLIKREIN; PROTEIN BINDING; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84940453609     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12657     Document Type: Article

References (35)

1. Schapira M, Scott CF, Colman RW,. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-468.
2. Pixley RA, Schapira M, Colman RW,. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-1729.
3. Sim RB, Reboul A, Arlaud GJ, Villiers CL, Colomb MG,. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett 1979; 97: 111-115.
4. Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ,. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J Biol Chem 2001; 276: 40880-40887.
5. Davis AE, Mejia P, Lu F,. Biological activities of C1 inhibitor. Mol Immunol 2008; 45: 4057-4063.
6. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, et al., Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995; 85: 1517-1526.
7. Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE,. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179: 3966-3972.
8. Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al., Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008; 121: 429-433.
9. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al., The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-33296.
10. Kaplan AP, Joseph K,. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol 2014; 121: 41-89.
11. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C,. In vivo roles of factor XII. Blood 2012; 120: 4296-4303.
12. Björkqvist J, Sala-Cunill A, Renné T,. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-374.
13. Revak SD, Cochrane CG,. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest 1976; 57: 852-860.
14. Schapira M,. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemost 1987; 13: 69-78.
15. Harpel PC, Lewin MF, Kaplan AP,. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem 1985; 260: 4257-4263.
16. Kerr FK, Thomas AR, Wijeyewickrema LC, Whisstock JC, Boyd SE, Kaiserman D, et al., Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol Immunol 2008; 45: 670-677.
17. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W,. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-354.
18. Bork K, Hardt J, Witzke G,. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-697.
19. Maurer M, Magerl M, Metz M, Siebenhaar F, Weller K, Krause K,. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013; 68: 816-819.
20. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al., Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-616.
21. Wagenaar-Bos IGA, Drouet C, Aygören-Pursun E, Bork K, Bucher C, Bygum A, et al., Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008; 338: 14-20.
22. Joseph K, Bains S, Tholanikunnel BG, Bygum A, Aabom A, Koch C, et al., A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes. Allergy 2015; 70: 115-119.
23. Ghannam A, Defendi F, Favier B, Drouet C,. Method for dosing the control capacity of C1Inh. Patent Application (Application #20140315232 issued October 23, 2014)-Justia Patents Database. http://patents.justia.com/patent/20140315232 (accessed 12 January 2015).
24. Thelwel C, Rigsby P, Longstaff C, ISTH-SSC Subcommittee on Factor XI and Contact System. An international collaborative study to establish the WHO 1st international standards for C1-inhibitor, plasma and concentrate. J Thromb Haemost 2011; 9: 2097-2099.
25. Joseph K, Tuscano TB, Kaplan AP,. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101: 279-286.
26. Drouet C, Alibeu C, Ponard D, Arlaud GJ, Colomb MG,. A sensitive method to assay blood complement C1 inhibitor activity. Clin Chim Acta 1988; 174: 121-130.
27. Martin L, Raison-Peyron N, Nöthen MM, Cichon S, Drouet C,. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol 2007; 120: 975-977.
28. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW,. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660-2667.
29. Reshef A, Moldovan D, Obtulowicz K, Leibovich I, Mihaly E, Visscher S, et al., Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013; 68: 118-124.
30. Lõpez-Lera A, Favier B, de la Cruz RM, Garrido S, Drouet C, Lõpez-Trascasa M,. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol 2010; 126: 1307-1310.
31. Charignon D, Ghannam A, Defendi F, Ponard D, Monnier N, Lõpez Trascasa M, et al., Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype. Allergy 2014; 69: 1659-1665.
32. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ, et al., Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72: 1841-1848.
33. De Smet BJ, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE,. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993; 81: 56-61.
34. Cugno M, Nuijens J, Hack E, Eerenberg A, Frangi D, Agostoni A, et al., Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1990; 85: 1215-1220.
35. Konings J, Cugno M, Suffritti C, Ten Cate H, Cicardi M, Govers-Riemslag JWP,. Ongoing contact activation in patients with hereditary angioedema. PLoS One 2013; 8: e74043.